Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Sera Prognostics ( (SERA) ).
On September 5, 2025, Sera Prognostics presented a new investor presentation at the H.C. Wainwright 27th Annual Global Investment Conference. The company highlighted its strategic focus on commercializing the PreTRM® test, supported by a strong financial position with $108.5 million in cash and marketable securities. Sera Prognostics aims to address the significant economic burden of preterm births in the U.S., which account for a substantial portion of neonatal healthcare costs. The company is progressing with Medicaid engagement and anticipates a commercial inflection point as it continues to expand its market presence.
The most recent analyst rating on (SERA) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Sera Prognostics stock, see the SERA Stock Forecast page.
Spark’s Take on SERA Stock
According to Spark, TipRanks’ AI Analyst, SERA is a Neutral.
Sera Prognostics’ overall stock score is primarily impacted by its weak financial performance, characterized by persistent losses and negative cash flows. While the earnings call provided some positive strategic insights, the ongoing financial challenges and negative valuation metrics weigh heavily on the stock’s attractiveness. Technical analysis shows mixed signals, contributing to a cautious outlook.
To see Spark’s full report on SERA stock, click here.
More about Sera Prognostics
Sera Prognostics, Inc. operates in the women’s health diagnostics industry, focusing on predictive diagnostics for pregnancy care. Their flagship product, PreTRM®, is a blood-based test that predicts the risk of spontaneous preterm birth, aiming to improve maternal and neonatal outcomes while reducing healthcare costs.
Average Trading Volume: 349,271
Technical Sentiment Signal: Sell
Current Market Cap: $129.8M
See more insights into SERA stock on TipRanks’ Stock Analysis page.